Pulmonary arterial hypertension trials in Portugal

In Portugal 8 Also abroad 305

8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Where
Almada, Lisbon, Porto
Age
18 years and over
People
85 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-513613-12-00 · EU 2024-513613-12-00
Phase 4Taking people
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Where
Almada, Lisbon
Age
18 years to 75 years
People
110 worldwide
Run by
AOP Orphan Pharmaceuticals AG
See details and how to joinNCT06317805 · EU 2023-504351-26-01
Phase 3Taking people
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Almada, Lisbon
Age
18 years and over
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07179380 · EU 2025-521558-40-00
Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Where
Almada, Coimbra, Porto
Age
18 years to 80 years
People
344 worldwide
Run by
Liquidia Technologies, Inc.
See details and how to joinNCT07285655
Phase 3Taking people
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Where
Coimbra, Lisbon, Porto, Vila Nova de Gaia
Age
18 years to 75 years
People
330 worldwide
Run by
Gossamer Bio USA, Inc.
See details and how to joinNCT06274801 · EU 2023-506334-75-00
Phase 3Enrolling by invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Where
Almada, Coimbra, Lisbon, Porto
Age
18 years and over
People
1,000 worldwide
Run by
United Therapeutics
See details and how to joinNCT03683186 · EU 2023-509305-68-00
Phase 3Taking people
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Where
Almada, Lisbon, Porto
Age
18 years to 75 years
People
486 worldwide
Run by
Inhibikase Therapeutics
See details and how to joinNCT07365332 · EU 2024-520218-23-00
Phase 1/2Taking people
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Where
Almada, Lisbon
Age
18 years to 100 years
People
232 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06649110